Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.69 |
| ▸ | POLB | P06746 | 2/20 | 0.68 |
| ▸ | ESR1 | P03372 | 6/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.66 |
| ▸ | LTA4H | P09960 | 2/20 | 0.64 |
| ▸ | BACE1 | P56817 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18265845 | 0.99 | HRH3 (0.71) | HRH3POLBESR1KDM4EGAA | |
| SCHEMBL2741672 | 0.99 | HRH3 (0.71) | HRH3POLBESR1KDM4EGAA | |
| SCHEMBL18595108 | 0.99 | HRH3 (0.71) | HRH3POLBESR1KDM4EGAA | |
| SCHEMBL19172409 | 0.99 | HRH3 (0.71) | HRH3POLBESR1KDM4EGAA | |
| Hydrochloric Acid SCHEMBL224629 | 0.97 | HRH3 (0.70) | HRH3POLBESR1KDM4EGAA | |
| SCHEMBL2089187 | 0.93 | HRH3 (0.75) | HRH3POLBESR1KDM4EKMT2A | |
| SCHEMBL2087381 | 0.92 | HRH3 (0.77) | HRH3ESR1KDM4EKMT2A | |
| SCHEMBL11809078 | 0.90 | ESR1 (0.65) | HRH3POLBESR1KDM4EGAA | |
| SCHEMBL11805107 | 0.89 | ESR1 (0.67) | HRH3POLBESR1KDM4EGAA | |
| SCHEMBL11803296 | 0.89 | ESR1 (0.67) | HRH3POLBESR1KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170210748-A1 | ASK 1 INHIBITING PYRROLOPYRIMIDINE DERIVATIVES | Convergence Pharmaceuticals Limited (GB) | 2017-07-27 | — | — | US | disclosed |
| US-20170210748-A1 | ASK 1 INHIBITING PYRROLOPYRIMIDINE DERIVATIVES | Convergence Pharmaceuticals Limited (GB) | 2017-07-27 | — | — | US | disclosed |
| US-20170210748-A1 | ASK 1 INHIBITING PYRROLOPYRIMIDINE DERIVATIVES | Convergence Pharmaceuticals Limited (GB) | 2017-07-27 | — | — | US | disclosed |
| US-9585886-B2 | ASK1 inhibiting pyrrolopyrimidine derivatives | CALCHAN LIMITED (GB) | 2017-03-07 | — | — | US | disclosed |
| US-9585886-B2 | ASK1 inhibiting pyrrolopyrimidine derivatives | CALCHAN LIMITED (GB) | 2017-03-07 | — | — | US | disclosed |
| US-9585886-B2 | ASK1 inhibiting pyrrolopyrimidine derivatives | CALCHAN LIMITED (GB) | 2017-03-07 | — | — | US | disclosed |
| EP-2651417-B1 | ASK1 INHIBITING PYRROLOPYRIMIDINE DERIVATIVES | CALCHAN LTD (GB) | 2016-11-30 | — | — | EP | disclosed |
| EP-2651417-B1 | ASK1 INHIBITING PYRROLOPYRIMIDINE DERIVATIVES | CALCHAN LTD (GB) | 2016-11-30 | — | — | EP | disclosed |
| US-20160067251-A1 | ASK 1 INHIBITING PYRROLOPYRIMIDINE DERIVATIVES | GALAPAGOS NV (BE) | 2016-03-10 | — | — | US | disclosed |
| US-20160067251-A1 | ASK 1 INHIBITING PYRROLOPYRIMIDINE DERIVATIVES | GALAPAGOS NV (BE) | 2016-03-10 | — | — | US | disclosed |
| EP-2651417-A1 | ASK1 INHIBITING PYRROLOPYRIMIDINE DERIVATIVES | Convergence Pharmaceuticals Limited (GB) | 2013-10-23 | — | — | EP | disclosed |
| US-8541363-B2 | Pyruvamide compounds as inhibitors of dust mite group 1 peptidase allergen and their use | St George's Hosptial Medical School (GB) | 2013-09-24 | — | — | US | disclosed |
| US-8541363-B2 | Pyruvamide compounds as inhibitors of dust mite group 1 peptidase allergen and their use | St George's Hosptial Medical School (GB) | 2013-09-24 | — | — | US | disclosed |
| US-20130217617-A1 | Pyruvamide Compounds as Inhibitors of Dust Mite Group 1 Peptidase Allergen and Their Use | THE UNIVERSITY OF MANCHESTER (GB) | 2013-08-22 | — | — | US | disclosed |
| US-20130217617-A1 | Pyruvamide Compounds as Inhibitors of Dust Mite Group 1 Peptidase Allergen and Their Use | THE UNIVERSITY OF MANCHESTER (GB) | 2013-08-22 | — | — | US | disclosed |
| US-20120322722-A1 | Pyruvamide Compounds as Inhibitors of Dust Mite Group 1 Peptidase Allergen and Their Use | THE UNIVERSITY OF MANCHESTER (GB) | 2012-12-20 | — | — | US | disclosed |
| US-20120322722-A1 | Pyruvamide Compounds as Inhibitors of Dust Mite Group 1 Peptidase Allergen and Their Use | THE UNIVERSITY OF MANCHESTER (GB) | 2012-12-20 | — | — | US | disclosed |
| WO-2012080735-A1 | ASK1 INHIBITING PYRROLOPYRIMIDINE DERIVATIVES | Convergence Pharmaceuticals Limited (GB) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012080735-A1 | ASK1 INHIBITING PYRROLOPYRIMIDINE DERIVATIVES | Convergence Pharmaceuticals Limited (GB) | 2012-06-21 | — | — | WO | disclosed |
| WO-2011089396-A2 | PYRUVAMIDE COMPOUNDS AS INHIBITORS OF DUST MITE GROUP 1 PEPTIDASE ALLERGEN AND THEIR USE. | ST GEORGE'S HOSPITAL MEDICAL SCHOOL (GB) | 2011-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170210748-A1 | ASK 1 INHIBITING PYRROLOPYRIMIDINE DERIVATIVES | YES1, IRAK1, TBK1 | HRH3 3689/4885POLB 1913/4885ESR1 2030/4885 |
| US-20130217617-A1 | Pyruvamide Compounds as Inhibitors of Dust Mite Group 1 Peptidase Allergen and Their Use | PREP, DPEP1, DPP8 | HRH3 154/4885POLB 4313/4885ESR1 4251/4885 |
| US-20160067251-A1 | ASK 1 INHIBITING PYRROLOPYRIMIDINE DERIVATIVES | YES1, IRAK1, TBK1 | HRH3 3689/4885POLB 1913/4885ESR1 2030/4885 |
| US-20120322722-A1 | Pyruvamide Compounds as Inhibitors of Dust Mite Group 1 Peptidase Allergen and Their Use | PREP, DPEP1, PEPD | HRH3 155/4885POLB 4181/4885ESR1 4215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.